Understand the source comparison
Peptides for Kidney Health Protocol Evidence Guide: Research vs Clinical Practice
BPC-157 eNOS stabilisation, microvascular protection 10–100 μg/kg daily × 7 days Multiple animal models, no human RCTs Within 24 hours of injury Strongest evidence for acute ischemia-reperfusion injury; timing-dependent Thymosin Beta-4 Actin polymerisation, ep
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- eNOS stabilisation, microvascular protection
- 10–100 μg/kg daily × 7 days
- Multiple animal models, no human RCTs
- Within 24 hours of injury
- Strongest evidence for acute ischemia-reperfusion injury; timing-dependent
- Thymosin Beta-4
- Actin polymerisation, epithelial migration
- 6–30 mg/kg twice weekly × 4 weeks
- Published in peer-reviewed nephrology journals
- Days 3–21 post-injury
- Effective for tubular repair when epithelium remains viable; no benefit in end-stage fibrosis
- KPV
- NF-κB inhibition, cytokine suppression
- 1–5 mg/kg daily × 7–14 days
- Limited renal-specific studies; mechanism extrapolated from IBD research
- During active inflammation phase (24–72h acute, continuous chronic)
- Narrow therapeutic window; ineffective once inflammation resolves
- Cartalax
- Telomere preservation, cellular senescence reduction
- 10 μg daily × 10–20 days
- Primarily Russian literature; limited Western validation
- Preventive or early-stage CKD
- Theoretical benefit in slowing progression; lacks robust dose-response data